Investigators are exploring concurrent PARP inhibition and definitive regional radiotherapy in patients with metastatic invasive cervical cancer in an ongoing phase I/II study.
Ghanshyam Yadav, MD, discusses the differences between type 1 and type 2 uterine cancer.
The group of researchers is conducting the largest African-American prostate cancer study ever, aiming to include 10,000 men nationwide.
Baylor College of Medicine has been awarded more than $17.4 million by the Cancer Prevention & Research Institute of Texas to support new cancer research and programs, core facilities and recruitment of new faculty.
Shoba A. Navai, MD, an assistant professor, Department of Pediatrics, Section of Pediatric Hematology and Oncology, at Baylor College of Medicine, Texas Children’s Hospital, discusses treatment options for patients with relapsed/refractory sarcoma.
Benjamin Leon Musher, MD, associate professor of medicine, hematology and oncology, at Baylor College of Medicine, discusses emerging combination therapies in hepatocellular carcinoma (HCC).
Benjamin Leon Musher, MD, reflects on the progress that has been made in hepatocellular carcinoma and highlights promising combinations that are emerging in the space.
Ghanshyam Yadav, MD, first-year resident, Baylor College of Medicine, discusses the combination of olaparib (Lynparza) and neratinib (Nerlyx) in patients with HER2-overexpressing uterine serous carcinoma.